| Review of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer M Sun, MO Niaz, A Nelson, M Skafida, MJ Niaz Cureus 12 (6), 2020 | 51 | 2020 |
| Prostate-specific membrane antigen uptake and survival in metastatic castration-resistant prostate cancer PJ Vlachostergios, MJ Niaz, M Sun, SA Mosallaie, C Thomas, PJ Christos, ... Frontiers in oncology 11, 630589, 2021 | 50 | 2021 |
| Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate … JS Batra, MJ Niaz, YE Whang, A Sheikh, C Thomas, P Christos, ... Urologic Oncology, 2020 | 42 | 2020 |
| Antibody-Drug Conjugates in Bladder Cancer P Vlachostergios, C Jakubowski, MJ Niaz, A Lee, C Thomas, AL Hackett, ... Bladder Cancer 4 (3), 247-259, 2018 | 38 | 2018 |
| Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC). ST Tagawa, M Sun, AO Sartor, C Thomas, S Singh, M Bissassar, ... Journal of Clinical Oncology 39 (15_suppl), 5015-5015, 2021 | 35 | 2021 |
| Pilot Study of Hyperfractionated Dosing of Lutetium‐177–Labeled Antiprostate‐Specific Membrane Antigen Monoclonal Antibody J591 (177Lu‐J591) for Metastatic … MJ Niaz, JS Batra, RD Walsh, MK Ramirez‐Fort, S Vallabhajosula, ... The oncologist 25 (6), 477-e895, 2020 | 35 | 2020 |
| Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC) ST Tagawa, J Osborne, MJ Niaz, S Vallabhajosula, PJ Vlachostergios, ... Journal of Clinical Oncology, 2020 | 28 | 2020 |
| Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer MO Niaz, M Sun, MK Ramirez-Fort, MJ Niaz Cureus 12 (2), 2020 | 25 | 2020 |
| Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (Part I Defining the Organ at Risk for … MK Ramirez-Fort, MJ Rogers, R Santiago, SS Mahase, MJ Niaz, ... Reports of Practical Oncology & Radiotherapy 3 (25), 367‐375, 2020 | 24 | 2020 |
| Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer M Sun, MJ Niaz, MO Niaz, ST Tagawa Current Oncology Reports 23 (5), 1-11, 2021 | 22 | 2021 |
| Review of commonly used prostate specific PET tracers used in prostate cancer imaging in current clinical practice MJ Niaz, M Sun, M Skafida, MO Niaz, J Ivanidze, J Osborne, E O'Dwyer Clinical Imaging, 2021 | 21 | 2021 |
| Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer PJ Vlachostergios, MJ Niaz, M Skafida, SA Mosallaie, C Thomas, ... The Prostate 81 (5), 279-285, 2021 | 20 | 2021 |
| Review of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for the treatment of metastatic castration-resistant prostate cancer MO Niaz, M Sun, MK Ramirez-Fort, MJ Niaz Cureus 12 (2), 2020 | 20 | 2020 |
| Functional outcome after decompressive craniectomy in patients with dominant or non-dominant malignant middle cerebral infarcts BK Alam, AS Bukhari, S Assad, PM Siddique, H Ghazanfar, MJ Niaz, ... Cureus 9 (1), 2017 | 19 | 2017 |
| Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC) ST Tagawa, JR Osborne, A Hackett, MJ Niaz, V Cooley, P Christos, ... Annals of Oncology 30 (Supplement_5), mdz248. 006, 2019 | 16 | 2019 |
| Dermatofibrosarcoma protuberans: The current state of multidisciplinary management MK Ramirez-Fort, B Meier-Schiesser, MJ Niaz, MO Niaz, A Feily, M Fort, ... Skinmed 18 (5), 288-293, 2020 | 14 | 2020 |
| Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC) ST Tagawa, J Osborne, E Fernandez, C Thomas, MJ Niaz, A Ciriaco, ... Journal of Clinical Oncology 38 (45), 2020 | 13 | 2020 |
| Pilot study of the diagnostic utility of 89Zr‐df‐IAB2M and 68Ga‐PSMA‐11 PET imaging and multiparametric MRI in localized prostate cancer PJ Vlachostergios, MJ Niaz, C Thomas, PJ Christos, JR Osborne, ... The Prostate 82 (4), 483-492, 2022 | 11 | 2022 |
| Comparison of Prostate-Specific Membrane Antigen-Targeted Radionuclide Therapy with Lutetium-177 via Antibody J591 vs. Small Molecule Ligand PSMA-617 MJ Niaz*, M Skafida, J Osborne, D Nanus, A Molina, C Thomas, ... The Journal of Urology 203 (Supplement 4), e367-e367, 2020 | 11* | 2020 |
| Prostatic irradiation-induced sexual dysfunction: A review andmultidisciplinary guide to management in the radical radiotherapy era(Part II on Urological Management) MJ Rogers, MK Ramirez-Fort, JA Kashanian, SA Broster, J Matta, ... Reports of Practical Oncology & Radiotherapy, 2020 | 7 | 2020 |
Panagiotis J VlachostergiosDivision of Hematology and Medical Oncology, New York-Presbyterian / Weill Cornell Medical Center在 nyp.org 的电子邮件经过验证
